Anti-Rheumatic Rx
David Liew drdavidliew
3 months ago
Hydroxychloroquine in SLE is all about the sweet spot. Not too hot with retinopathy, not too cold with flares, just right by the levels.
Yet drug concentrations and TDM are not commonplace in many places - time for change
Laura Coates in the #ACR25 meeting review @RheumNow https://t.co/oB3ecfSQQc
Jiha Lee JihaRheum
3 months ago
Year in Preview
GCA: GC over-prescribed, bDMARDs more effective than MTX, and more options available (TOC, JAKi)
@RheumNow #ACR25 https://t.co/L9fx1LCCnw
David Liew drdavidliew
3 months ago
“We’ve got to do better for our patients with GCA” - Laura Coates, doing the #ACR25 meeting review
She told us she is speaking about diseases outside her comfort zone but she is bang on.
As she said: not good enough real world all the people not on steroid-sparing Rx
@RheumNow https://t.co/4WiEORwPgI
David Liew drdavidliew
3 months ago
Sjogren’s disease: is it maybe true you need to still have some salivary function left to get benefit from therapy?
Ianalumab (BAFF inh) ph3 NEPTUNUS-1/2
Very decent on primary (ESSDAI) & we will see this
Salivary flow only improved when some at baseline
#ACR25 LB24 @RheumNow https://t.co/uGwKdN3Dsh
Aurelie Najm AurelieRheumo
3 months ago
Effectiveness of b/tsDMARDs RA pts kidney dysfunction
CorEvitas RA registry 9,569 pts
Pts low eGFR = older more comorbidities less NSAIDs
Reduced eGFR = 30% less likely to achieve remission
Persists indeed of GC intake
Is it a PK/PD related issue or somehow the reflection of https://t.co/KZuvPVa6eg
Jiha Lee JihaRheum
3 months ago
b/tsDMARD in RA + CKD (eGFR <60)
From >12K pts in CorEvitas:
- overall effective but 30% ↓ CDAI-emission (HR 0.71)
- Findings consistent across TNFi, IL-6i, ABA BCDT, JAKi
@RheumNow #ACR25 A#2640 https://t.co/UOP9ejZKoA
Day 3 in Chicago is hump day, the last big full day of presentations and posters. The day began with an 8AM plenary session, which brings me to the first of my three notables from today:
Aurelie Najm AurelieRheumo
3 months ago
We often see patients with MTX lab abnormalities but How frequent is MTX toxicity?
Retrospective study 2500pts
Rochester Epidemiology Project cohort
60% w/ ever lab abnormalities, but 4% attributed to MTX 0.87/100 patient year
Organ injury event 0.02/100 patient year = 5 in https://t.co/w8oYUjj5Yp
Methotrexate (MTX) remains the cornerstone of rheumatoid arthritis (RA) treatment, yet it remains unclear as to how to predict who will respond to it. Two studies presented at ACR (Abstracts 2639 and 2643) suggest the answer may be hiding in the gut.
Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at ACR Convergence 2025. Below are several of the best abstracts from Day 3, as chosen by our outstanding faculty.
At ACR 2025, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological aging and to consider how nutrition and exercise can serve as integrative lifestyle interventions.
David Liew drdavidliew
3 months ago
DMARD exposure overall during pregnancy is not associated with severe maternal or neonatal morbidity, in this Ontario cohort.
We’re getting better at finding a balance with DMARDs that is safe for both mother and baby. Blanket resistance is harmful
#ACR25 ABST2627 @RheumNow https://t.co/oDOpySGS3N
Bella Mehta bella_mehta
3 months ago
Large Canada ICES dataset- DMARD use is not associated with adverse pregnancy outcomes. In pts with RA, SlE and other rheumatic diseases.
Abst#2627 #ACR25 @RheumNow https://t.co/T9Ll1FNjT7
sheila RHEUMarampa
3 months ago
Predictors of retinopathy progression after HCQ discontinued?
In the chart review of 28 pt records who had retinopathy, 35% progressed despite d/c
Age - significant assoc'n with progression
✳️monitor toxicity more closely esp in older pts
#ACR25 @RheumNow Abs2444 https://t.co/9rf2RQAgRQ
Poster Hall